SciVision Biotech Inc
TWSE:1786
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
SciVision Biotech Inc
Total Receivables
SciVision Biotech Inc
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
SciVision Biotech Inc
TWSE:1786
|
Total Receivables
NT$243.7m
|
CAGR 3-Years
39%
|
CAGR 5-Years
29%
|
CAGR 10-Years
14%
|
|
|
M
|
Medtecs International Corporation Ltd
SGX:546
|
Total Receivables
$19.3m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
V
|
Visco Vision Inc
TWSE:6782
|
Total Receivables
NT$577.8m
|
CAGR 3-Years
19%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
P
|
Pegavision Corp
TWSE:6491
|
Total Receivables
NT$967.1m
|
CAGR 3-Years
9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
OK Biotech Co Ltd
TWSE:4155
|
Total Receivables
NT$527m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
SciVision Biotech Inc
Glance View
SciVision Biotech, Inc. engages in the research, development, and production of hyaluronic acid medical products. The company is headquartered in Kaohsiung, Kaohsiung. The company went IPO on 2010-12-29. The firm primarily provides subcutaneous fillers for plastic surgery facial injection, joint cavity injections for orthopedics use, as well as hyaluronic acid raw materials, among others. The firm is also involved in deoxyribonucleic acid (DNA) identification, detection, sequencing and application, as well as the manufacturing of care products and foods. The firm operates its business in the Americas, Europe, Asia, Middle East and Africa.
See Also
What is SciVision Biotech Inc's Total Receivables?
Total Receivables
243.7m
TWD
Based on the financial report for Dec 31, 2025, SciVision Biotech Inc's Total Receivables amounts to 243.7m TWD.
What is SciVision Biotech Inc's Total Receivables growth rate?
Total Receivables CAGR 10Y
14%
Over the last year, the Total Receivables growth was 40%. The average annual Total Receivables growth rates for SciVision Biotech Inc have been 39% over the past three years , 29% over the past five years , and 14% over the past ten years .
